Safety and Immunogenicity of a Human Papillomavirus    Peptide Vaccine (CIGB-228) in Women with High-Grade  Cervical Intraepithelial Neoplasia: First-in-Human, Proof-of-Concept Trial

<table>Schematic overview of vaccination scheme.</table>

International Scholarly Research Notices

fig1

Figure 1

Figure 1: Safety and Immunogenicity of a Human Papillomavirus    Peptide Vaccine (CIGB-228) in Women with High-Grade  Cervical Intraepithelial Neoplasia: First-in-Human, Proof-of-Concept Trial 

Figure 1 | Safety and Immunogenicity of a Human Papillomavirus    Peptide Vaccine (CIGB-228) in Women with High-Grade  Cervical Intraepithelial Neoplasia: First-in-Human, Proof-of-Concept Trial 